Brickell Biotech (BBI) Stock Price
Brickell Biotech Price
Revenue at Brickell Biotech has contracted by 0.8% per year over the past 19 years to 6.94 M USD. Brickell Biotech's net margin stands at -303.9%, up from -1,002.1% several years earlier. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Brickell Biotech stock price
Brickell Biotech business model & stock analysis
Frequently asked questions about Brickell Biotech
Brickell Biotech Inc's business model focuses on the development and commercialization of innovative therapeutics for various skin conditions. With a strong emphasis on dermatology, the company aims to address unmet medical needs through cutting-edge research and development. By harnessing its proprietary delivery technologies and expertise in drug development, Brickell Biotech Inc strives to bring novel treatment options to patients suffering from conditions like hyperhidrosis and other dermatologic disorders. The company's commitment to advancing scientific knowledge and delivering effective therapies underscores its mission to improve patients' lives and enhance skin health.
Brickell Biotech Inc is primarily active in the healthcare and pharmaceutical industries. As a leading company in the field, Brickell Biotech focuses on the development and commercialization of innovative therapeutics for the treatment of various skin diseases, such as hyperhidrosis and acne. With its cutting-edge research and advanced formulations, Brickell Biotech aims to provide effective solutions that improve the lives of patients worldwide. By revolutionizing the dermatological market, Brickell Biotech Inc continues to establish itself as a key player in the healthcare industry, delivering innovative products backed by scientific expertise and a commitment to patient care.
The main competitors of Brickell Biotech Inc in the market are other pharmaceutical companies that focus on the development and commercialization of novel therapeutics. These may include companies such as Johnson & Johnson, Pfizer, Merck & Co., Inc., Bristol Myers Squibb, and Novartis.
Brickell Biotech Inc is a pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in 2009, Brickell Biotech has established a strong presence in the dermatology and infectious disease markets. With a mission to improve patients' lives, the company focuses on developing novel treatments addressing unmet medical needs. Brickell Biotech has a rich history of successful research and development, collaborating with leading clinicians and scientists. Its dedication to innovation and commitment to quality has positioned the company as a trusted healthcare partner. Brickell Biotech's continuous efforts in advancing medical solutions highlight its dedication to improving global health.
Brickell Biotech Inc has achieved significant milestones in its journey. These include the FDA approval of its novel therapeutic, sofpironium bromide gel, for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweating. This milestone demonstrates the company's commitment to addressing unmet medical needs. Furthermore, Brickell Biotech Inc has successfully completed Phase 3 clinical trials, showcasing the efficacy and safety of its product. The company's achievements reflect its dedication to developing innovative solutions to improve patients' quality of life. Brickell Biotech Inc's FDA approval and completion of pivotal trials signify substantial progress towards becoming a leading pharmaceutical player in the dermatology market.
Brickell Biotech Inc is primarily present in the United States.
Brickell Biotech Inc represents values of innovation, integrity, and dedication to improving patient lives. With a strong corporate philosophy focused on developing transformative therapeutics, Brickell Biotech is dedicated to advancing dermatology solutions for unmet medical needs. The company's commitment to excellence is reflected in its research and development efforts to bring novel treatments to market. Brickell Biotech's approach emphasizes collaboration, leveraging scientific expertise, and fostering strong relationships with healthcare professionals. By prioritizing patient well-being and employing cutting-edge technologies, Brickell Biotech Inc strives to make a positive impact on the lives of individuals with dermatological conditions.
8 analysts currently rate the Brickell Biotech stock: 6 recommend buying, 2 holding and 0 selling.
The Brickell Biotech share (BBI) is listed on 1 stock exchanges, including: NASDAQ (BBI).
Brickell Biotech Inc is an American biopharmaceutical company specializing in the development of products for the treatment of skin disorders. The company was founded in 2009 and is headquartered in Boulder, Colorado.
The revenue cannot currently be calculated for Brickell Biotech.
The profit cannot currently be calculated for Brickell Biotech.
The P/E ratio cannot be calculated for Brickell Biotech at the moment.
The P/S cannot be calculated for Brickell Biotech currently.
The Eulerpool Quality Score for Brickell Biotech is 2/10.
The ISIN of Brickell Biotech is US10802T1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Brickell Biotech is A2PRDX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Brickell Biotech is BBI. The ticker symbol is used to trade Brickell Biotech shares on the stock exchange.
Brickell Biotech stock
Brickell Biotech Peer Group
Brickell Biotech Ticker
Brickell Biotech FIGI
All fundamentals and in-depth analysis of Brickell Biotech
Our stock analysis for Brickell Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Brickell Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.